Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment

K. Chroma, Z. Skrott, J. Gursky, J. Bacovsky, P. Moudry, T. Buchtova, M. Mistrik, J. Bartek

. 2022 ; 13 (3) : 203. [pub] 20220304

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protein degradation is particularly toxic to MM cells as they typically accumulate large amounts of toxic proteins. However, MM cells often acquire resistance to PIs through aberrant expression or mutations of proteasome subunits such as PSMB5, resulting in disease recurrence and further treatment failure. Here we propose CuET-a proteasome-like inhibitor agent that is spontaneously formed in-vivo and in-vitro from the approved alcohol-abuse drug disulfiram (DSF), as a readily available treatment effective against diverse resistant forms of MM. We show that CuET efficiently kills also resistant MM cells adapted to proliferate under exposure to common anti-myeloma drugs such as bortezomib and carfilzomib used as the first-line therapy, as well as to other experimental drugs targeting protein degradation upstream of the proteasome. Furthermore, CuET can overcome also the adaptation mechanism based on reduced proteasome load, another clinically relevant form of treatment resistance. Data obtained from experimental treatment-resistant cellular models of human MM are further corroborated using rather unique advanced cytotoxicity experiments on myeloma and normal blood cells obtained from fresh patient biopsies including newly diagnosed as well as relapsed and treatment-resistant MM. Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019223
003      
CZ-PrNML
005      
20220804135439.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41419-022-04651-w $2 doi
035    __
$a (PubMed)35246527
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Chroma, Katarina $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000301410469
245    12
$a A drug repurposing strategy for overcoming human multiple myeloma resistance to standard-of-care treatment / $c K. Chroma, Z. Skrott, J. Gursky, J. Bacovsky, P. Moudry, T. Buchtova, M. Mistrik, J. Bartek
520    9_
$a Despite several approved therapeutic modalities, multiple myeloma (MM) remains an incurable blood malignancy and only a small fraction of patients achieves prolonged disease control. The common anti-MM treatment targets proteasome with specific inhibitors (PI). The resulting interference with protein degradation is particularly toxic to MM cells as they typically accumulate large amounts of toxic proteins. However, MM cells often acquire resistance to PIs through aberrant expression or mutations of proteasome subunits such as PSMB5, resulting in disease recurrence and further treatment failure. Here we propose CuET-a proteasome-like inhibitor agent that is spontaneously formed in-vivo and in-vitro from the approved alcohol-abuse drug disulfiram (DSF), as a readily available treatment effective against diverse resistant forms of MM. We show that CuET efficiently kills also resistant MM cells adapted to proliferate under exposure to common anti-myeloma drugs such as bortezomib and carfilzomib used as the first-line therapy, as well as to other experimental drugs targeting protein degradation upstream of the proteasome. Furthermore, CuET can overcome also the adaptation mechanism based on reduced proteasome load, another clinically relevant form of treatment resistance. Data obtained from experimental treatment-resistant cellular models of human MM are further corroborated using rather unique advanced cytotoxicity experiments on myeloma and normal blood cells obtained from fresh patient biopsies including newly diagnosed as well as relapsed and treatment-resistant MM. Overall our findings suggest that disulfiram repurposing particularly if combined with copper supplementation may offer a promising and readily available treatment option for patients suffering from relapsed and/or therapy-resistant multiple myeloma.
650    12
$a protinádorové látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a bortezomib $x farmakologie $x terapeutické užití $7 D000069286
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a disulfiram $x farmakologie $7 D004221
650    _2
$a přehodnocení terapeutických indikací léčivého přípravku $7 D058492
650    _2
$a chemorezistence $7 D019008
650    _2
$a lidé $7 D006801
650    12
$a mnohočetný myelom $x patologie $7 D009101
650    _2
$a lokální recidiva nádoru $x farmakoterapie $7 D009364
650    _2
$a proteasomový endopeptidasový komplex $x metabolismus $7 D046988
650    _2
$a inhibitory proteasomu $x farmakologie $x terapeutické užití $7 D061988
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Skrott, Zdenek $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000160043609
700    1_
$a Gursky, Jan $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic
700    1_
$a Bacovsky, Jaroslav $u Department of Hemato-oncology, University Hospital Olomouc and Medical Faculty of Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a Moudry, Pavel $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/000000021479007X
700    1_
$a Buchtova, Tereza $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic $1 https://orcid.org/0000000152331504
700    1_
$a Mistrik, Martin $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. martin.mistrik@upol.cz $1 https://orcid.org/0000000223210348
700    1_
$a Bartek, Jiri $u Laboratory of Genome Integrity, Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Czech Republic. jb@cancer.dk $u Danish Cancer Society Research Center, Copenhagen, Denmark. jb@cancer.dk $u Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Science for Life Laboratory, Karolinska Institute, Stockholm, Sweden. jb@cancer.dk $1 https://orcid.org/0000000320137525 $7 xx0046271
773    0_
$w MED00173233 $t Cell death & disease $x 2041-4889 $g Roč. 13, č. 3 (2022), s. 203
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35246527 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135433 $b ABA008
999    __
$a ok $b bmc $g 1822706 $s 1170466
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 13 $c 3 $d 203 $e 20220304 $i 2041-4889 $m Cell death & disease $n Cell Death Dis $x MED00173233
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...